AGL 6.45 Decreased By ▼ -0.05 (-0.77%)
ANL 9.50 Decreased By ▼ -0.20 (-2.06%)
AVN 74.95 Decreased By ▼ -0.88 (-1.16%)
BOP 5.35 Increased By ▲ 0.03 (0.56%)
CNERGY 4.80 Decreased By ▼ -0.05 (-1.03%)
EFERT 78.00 Increased By ▲ 0.51 (0.66%)
EPCL 54.15 Decreased By ▼ -1.06 (-1.92%)
FCCL 15.00 Decreased By ▼ -0.25 (-1.64%)
FFL 6.20 Decreased By ▼ -0.10 (-1.59%)
FLYNG 7.01 Increased By ▲ 0.16 (2.34%)
GGGL 10.05 Decreased By ▼ -0.12 (-1.18%)
GGL 15.94 Decreased By ▼ -0.37 (-2.27%)
GTECH 7.85 Increased By ▲ 0.41 (5.51%)
HUMNL 6.27 Decreased By ▼ -0.06 (-0.95%)
KEL 2.83 Decreased By ▼ -0.14 (-4.71%)
LOTCHEM 27.65 Decreased By ▼ -0.65 (-2.3%)
MLCF 27.00 Decreased By ▼ -0.56 (-2.03%)
OGDC 73.35 Decreased By ▼ -0.65 (-0.88%)
PAEL 15.30 Decreased By ▼ -0.29 (-1.86%)
PIBTL 5.15 Decreased By ▼ -0.10 (-1.9%)
PRL 16.10 Decreased By ▼ -0.48 (-2.9%)
SILK 1.04 Decreased By ▼ -0.02 (-1.89%)
TELE 10.45 Decreased By ▼ -0.20 (-1.88%)
TPL 7.69 Decreased By ▼ -0.19 (-2.41%)
TPLP 19.22 Decreased By ▼ -0.48 (-2.44%)
TREET 22.75 Decreased By ▼ -0.25 (-1.09%)
TRG 115.90 Decreased By ▼ -4.20 (-3.5%)
UNITY 21.80 Decreased By ▼ -0.34 (-1.54%)
WAVES 11.15 Decreased By ▼ -0.05 (-0.45%)
WTL 1.12 Decreased By ▼ -0.03 (-2.61%)
BR100 4,039 Decreased By -56.1 (-1.37%)
BR30 14,984 Decreased By -242.5 (-1.59%)
KSE100 40,620 Decreased By -307.7 (-0.75%)
KSE30 15,213 Decreased By -142.6 (-0.93%)
World

AstraZeneca suffers diabetes drug setback for Covid

  • The trial was carried out alongside Saint Luke's Mid America Heart Institute and looked at potential complications including diabetes and heart failure.
Published April 12, 2021
Follow us

LONDON: British pharmaceutical giant AstraZeneca on Monday said that following a trial, its diabetes drug Farxiga was not successful in treating Covid patients at risk of severe complications.

AstraZeneca, whose separate Covid vaccine rollout has been hampered by health concerns, said its trial "assessing the potential of Farxiga to treat patients hospitalised with Covid-19 who are at risk of developing serious complications... did not achieve statistical significance".

The trial was carried out alongside Saint Luke's Mid America Heart Institute and looked at potential complications including diabetes and heart failure.

"While the trial did not achieve statistical significance, the findings are very interesting and valuable, and will inform future clinical science," Saint Luke's cardiologist Mikhail Kosiborod said in a joint statement.

Public confidence in AstraZeneca's Covid-19 vaccine has meanwhile been badly shaken by reports linking it to rare, but potentially fatal, blood clots, and by conflicting recommendations over its use.

Comments

Comments are closed.